Cognitive strategies for early psychosis.
Official title: Cognitive Strategies in Early Psychosis 1
Run by University of Minnesota · NCT07231497 · Data updated 2026-11-12
This will try a single dose of modafinil in people without psychosis to see if it changes how they play decision-making brain games and their brain activity.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 35 Years |
| Sex | All |
| Enrollment | 103 (estimated) |
| Sponsor | University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Status | Recruiting |
| Started | October 31, 2025 |
| Main results expected | April 30, 2030 |
| Study ends | April 30, 2030 |
| Registry record updated | February 17, 2026 |
| Trial ID | NCT07231497 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who do not have psychosis, speak English, have estimated IQ ≥70, can attend two in-person visits, and have been clinically stable on any medications per study rules are the intended participants.
✕Probably not a fit
People with major neurological disorders, certain medical contraindications to modafinil, unstable psychiatric status, or who cannot travel to Minneapolis likely would not benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants complete two in-person visits roughly one week apart: an intake visit with interviews and questionnaires, and a longer EEG + medication visit at the University of Minnesota. At the EEG visit participants undergo safety screening (blood draw, urine drug test, breathalyzer), wear an EEG cap, complete computerized decision-making tasks, and receive a single dose of modafinil with repeat task/EEG recordings. Visits take about 30 minutes to 2.5 hours for intake (shorter if they participated in a sister study) and about 4–4.5 hours for the EEG/medication visit. The design compares task performance and EEG signals before and after the single modafinil dose to see acute drug-related changes.
Why it matters
Potential benefit: If successful, the results could improve understanding of decision-making brain processes relevant to psychosis and inform future treatment or cognitive interventions.
How similar studies have gone: Prior studies of modafinil for cognition and EEG have shown mixed but sometimes positive effects, so this approach builds on existing but not definitive evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * English proficiency, as determined by staff observation and participant self-report * Estimated IQ at or above 70, as estimated by the cognitive assessments * Is clinical stable, defined as outpatient status for at least one month prior to study participation * Has clinically stable doses of medication for at least one month prior to study participation as determined by the PI * Participants may have minor adjustments in medication doses in the past 30 days, per PI discretion, but may not have major increases or decreases in dosses, or additions or removal of medications in the past 30 days * Participants are to have no changes to medications in the past 7 days before study medication administration (i.e., must have been on a stable dose for at least 7 days prior to receiving the study drug). Exclusion Criteria: Medical criteria: * Presence of the following medical concerns, as determined by the study PI: * Major neurological disorder * History of head injury with or without prolonged consciousness * Any major medical condition that, in the opinion of the PI, would impede participation in the study or would put the participant at additional risk by participating * History of any of the following as reported by the participant: * Renal impairment, injury, or disease * Hepatic impairment, injury, or disease * Myocardial infarction or heart disease. * The following cardiac symptoms requiring medical follow-up that, in the opinion of the investigator, would impede participation in the study or would put the participant at additional risk by participating * Dsypnea * Palpitations * Orthopnea * Pedal oedema * Significant dizziness * Syncope * Claudication ---Low white blood cell count, or is diagnosed with leukopenia, neutropenia, or agranulocytosis * Presence of unmanaged hypertension (\>140/90) or elevated resting heart rate (\>100 bpm) * Abnormal clinical laboratory values: * uACR \> 30 mg/g * creatinine level \>0/95 mg/dL * AST or ALT \>50 U/L * Bilirubin \>1.2 mg/dL * Total Protein \<6 g/dL * Participant is pregnant, planning to become pregnant, or is breastfeeding * Participant cannot pass the visual acuity test (e.g., a score lower than 20/25 on the Snellen) * Takes medications or supplements that have major interactions with modafinil (e.g., ketamine, MAOIs, clomipramine, diazepam, propranolol, warfarin, amphetamine or dextroamphetamine, dexmethylphenidate or methylphenidate) * Has an allergy to modafinil * Is currently taking modafinil as a prescription * Has previously experienced Stevens-Johnson syndrome in response to taking a medication Mental health criteria: * Meets criteria for severe substance or alcohol use disorder within 3 months of enrollment * Lifetime history of stimulant use disorder * Meets criteria for clinical risk of suicidal behavior, as defined by: * Clinician judgment * Active suicidal ideation at screening or other appointments * Previous intent to act on suicidal ideation with a specific plan and/or preparatory acts within 6 months of enrollment * A suicide attempt within 6 months of enrollment * Meets criteria for a depressive episode within the past month as determined by the diagnostic interview or for a severe or extremely severe depressive episode in the abbreviated battery within the past month * Meets DSM-5 criteria for, or reports professional diagnosis of, a psychotic, bipolar, or autism spectrum disorder * Has a family history (1st degree relative) of psychotic, bipolar, or autism spectrum disorder * Is prescribed psychotropic medications or takes supplements with psychotropic effects (e.g., Nootropics) * Any other psychiatric symptoms or conditions that, in the opinion of the PI, would impede participation in the study or put the participant at additional risk by participating Other Criteria: * Unable or unwilling to provide informed consent * Unable to demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in the research study * Participant is illiterate * Have engaged in significant cognitive training, in the opinion of the PI, in the last year
Where it's running
-
University of Minnesota
Minneapolis, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Sophia Vinogradov, MD — University of Minnesota
- Study coordinator: Kaylee Enevold
- Email: costep1@umn.edu
- Phone: 612-403-4585
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can the Ronnie Gardiner Method improve thinking and daily function in people with Parkinson’s
In this 10-week program, adults with Parkinson’s disease will try the Ronnie Gardiner Method to see if it helps thinking, talking, movement, balance, and quality of life.
-
Beef-Protein Ready-to-Eat Meals to Support Firefighter Recovery
This study tests whether beef-based ready-to-eat meals help firefighters recover better after simulated firefighting tasks, compared with plant-based meals.
-
How pork protein affects recovery after simulated firefighting
This study tests whether pork-based meals help firefighters recover better and perform sooner after hard simulated fire drills, compared with plant-based meals or carbohydrate-focused meals.
-
LpD3.5 Intervention for Gut Health and Cognition in Older Adults with MCI
In older adults with mild cognitive impairment, this study tests whether daily LpD3.5 capsules can improve gut health and potentially cognition compared with placebo.
-
Ketone and Carbohydrate Supplementation in Endurance Cycling
This study tests whether adding ketones to a carb plan helps amateur endurance cyclists perform better and think more clearly during long, exhausting rides.
-
Appetite and Thinking Response to a Breakfast Cereal
This study tests how eating a ready-to-eat breakfast cereal affects appetite and thinking in healthy adults who regularly eat cereal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.